|
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
RECRUITINGPhase 3Sponsored by Amgen
Actively Recruiting
PhasePhase 3
SponsorAmgen
Started2024-07-17
Est. completion2028-01-31
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations26 sites
View on ClinicalTrials.gov →
NCT06252649
Summary
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Pathologically documented metastatic colorectal adenocarcinoma with KRAS p.G12C mutation by a locally validated assay. * Central laboratory detection of KRAS p.G12C mutation. * Measurable metastatic disease per RECIST v1.1 criteria. * Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1. * Adequate organ function. Exclusion Criteria: * Active, untreated brain metastases. * Leptomeningeal disease * Previous treatment with a KRAS p.G12C inhibitor * History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline CT scan
Conditions2
CancerMetastatic Colorectal Cancer
Interventions4
Locations26 sites
Ironwood Cancer and Research Centers Scottsdale
Providence Saint Jude Medical Center
City of Hope National Medical Center
Cancer and Blood Research Center, LLC
California Research Institute
Find trials near these locations
Cancer trials in Long BeachCancer trials in Los AngelesCancer trials in JacksonvilleCancer trials in AtlantaCancer trials in ChicagoCancer trials in PhiladelphiaCancer trials in NashvilleAll trials in ArizonaAll trials in CaliforniaAll trials in FloridaAll trials in GeorgiaAll trials in IllinoisAll trials in KentuckyAll trials in MissouriAll trials in North CarolinaAll trials in PennsylvaniaAll trials in Tennessee
Related trials
- Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer — ARCAGY/ GINECO GROUP
- Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer — National Cancer Institute, Naples
- Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) — Gruppo Oncologico del Nord-Ovest
- Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer — UNICANCER
- Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver — Federation Francophone de Cancerologie Digestive
- The Drug Rediscovery Protocol (DRUP Trial) — The Netherlands Cancer Institute
- The Sagittarius Trial — IFOM ETS - The AIRC Institute of Molecular Oncology
- ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer — National Cancer Institute, Naples
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 3
SponsorAmgen
Started2024-07-17
Est. completion2028-01-31
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations26 sites
View on ClinicalTrials.gov →
NCT06252649